
//- content para with bg
table
  tr
    td
      +spacer(20)
  tr
    td.px-global
      table
        tr
          td.text-lead In <strong class="text-secondary " style="color: #461e6c;">BRIGHT,</strong> U300 glargine demonstrated:
      +spacer(20)
      +list('powerful HbA<sub>1c</sub> reduction*<br>','lower rates and incidence of anytime<sup><small class="text-dark" style="color: black; font-size: 85%;">†</small></sup> hypoglycaemia during the active titration period*', 'Comparable incidence and rates of anytime<sup><small class="text-dark" style="color: black; font-size: 85%;">†</small></sup> hypoglycaemia thereafter*').px-global
  tr
    td
      +spacer(20)
  tr
    td.px-global when compared with U100 degludec in insulin-naïve patients with uncontrolled T2DM.<sup>1</sup><br><small class=".text-small">*Not the primary endpoint</small>
  tr
    td
      +spacer(20)
//- content para with bg